drugset / Trial / NCT00209261

A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)

NCT00209261

Phase 4 Completed 221 enrolled Ferring Pharmaceuticals
RandomizedCrossoverOpen-labelTreatment

Summary

To evaluate the preference of subjects for Minirin® oral lyophilisate treatment compared with Minirin® tablet treatment after 6 weeks. To compare efficacy of the 2 formulations at the end of the 6-week treatment period using diary card data. To compare ease of use of both formulations at 3 and 6 weeks using a VAS-scale. To validate a PNE Quality of Life (QoL) questionnaire. To evaluate safety. To compare compliance with the 2 formulations

Timeline

Start
2004-12
Primary completion
2005-08
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Desmopressin Peptide 120 ug Oral
Comparator Desmopressin Peptide 0.2 mg Oral
Comparator Desmopressin Peptide 240 ug Oral
Comparator Desmopressin Peptide 0.4 mg Oral